| 研究报告 |
|
|
|
|
| 重组血管活性肠肽的制备及鉴定 |
| 谢珊珊,余榕捷**,曾乐,李娟,王静静,洪岸 |
| 暨南大学生物工程研究所 广州 510632 |
|
| Preparation and Identification of Recombinant Vasoactive Intestinal Peptide |
| XIE Shan-shan,YU Rong-jie,ZENG Le,LI Juan,WANG Jing-jing,HONG An |
| Bio-engineering Institute of Jinan University, Guangzhou 510632, China |
| ［1］ |
Zhou H, Huang J,Murthy K S,et al . Molecular cloning and functional expression of a VIP specific receptor.AmJ Physiol G astrointest Liver Physiol,2006,291(4):G728~734
|
| ［2］ |
Said S I, Mutt V. Polypeptide with broad biological activity:isolation from small intestine. Science, 1970, 169(951):1217~1218
|
| ［3］ |
Arimura A. Perspectives on pituitary adenylate cyclaseactivating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn J Physiol, 1998, 48(5):301~331
|
| ［4］ |
Laburthe M, Couvinean A. Molecular pharmacology and structureof VPAC receptors for VIP and PACAP. J Regul pept, 2002, 108(2-3):165~173
|
| ［5］ |
Mackay M,Fantes J,Scherer S,et al. Chromosomallocalization in mouse and human of the vasoactive intestinal peptide receptor type2 gene: a possible contributor to the holoprosencephaly 3 phenotype. Genomics, 1996, 37(3):345~353
|
| ［6］ |
Abad C,Niewiadomski P,Dawn HsiaoWei Loh,et al . Neuro－transmitter and immunomodulators actions of VIP and PACAP: lessons from knockout mice. Int J Pept Res,2006,12(3):297~310
|
| ［7］ |
Fahrenkrug J. Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function. Digestion, 1979，19(3):149~169
|
| ［8］ |
Lundberg P, Lie A, Bjurholm A,et al. Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. J Bone, 2000, 27(6): 803~810
|
| ［9］ |
Kim S W, Beauchamp R D, Townsend C M Jr, et al. Vasoactive intestinal polypeptide inhibits cmyc expression and growth of human gastric carcinoma cells. Surgery, 1991, 110(2):270~276
|
| ［10］ |
Delgado M, Munoz Elias E J, Gomariz R P, et al. Vasoactiveintestinal peptide and pituitary adenylate cyclase activating polypeptideenhance IL 10 production by murine macrophages: in vitro and in vivo studies. J Immunol, 1999, 162(3):1707~1716
|
| ［11］ |
Whittle B J R, Morshita T ohy Y.Microrasoular action of plareleractivating factior on rat gastric mucosa and submucosa. Am J physiol, 1996, 251: G772~778
|
| ［12］ |
Schebalin M, Said S I, Makhlouf G M .Stimulation of insulin and glucagon secretion by vasoactive intestinal peptide. Am J Physiol, 1977, 232(2):E 197~E 200
|
| ［13］ |
MasmoudiKouki O, Gandolfo P, Castel H,et al . Role of PACAP and VIP in astroglial functions. Peptides. 2007 ,28(9):1753~60
|
| ［14］ |
Kang S W, Youngren O M,El Halawani M E,et al .Influence of VIP on prolactinemia in turkey anterior pituitary cells: role of cAMP second messenger in VIPinduced prolactin gene expression regulatory . Peptides, 2002,109(1-3)：39~44(6)
|
| ［15］ |
Cazillis M, Gonzalez B J, Billardon C,et al .VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells.Eur J Neurosci，2004 ,19(4):798~808
|
| ［16］ |
Sald S I. Vasoactive intestinal peptide. J Endocrinol Invest, 1986,9(2):191~200
|
| ［17］ |
Allam G. Vasoactive intestinal peptide inhibits liver pathology in acute murine schistosomiasis mansoni and modulates IL10, IL12 and TNFalpha production. Immunobiology, 2007,212(8):603~12
|
| ［18］ |
Hauner H,Glatting G,Kaminska D, et al . Effect of vasoactive intestinal polypeptide (VIP) on glucose and lipid metabolism of isolated rat adipocytes. Research in Experimental Medicine，2005，10（1007）：189~195
|
| ［19］ |
Edward J,Derek R,Jeffrey L K, et al . Specific recognition of the human neuroendocrine receptor for vasoactive intestinal peptide by antipeptide antibodies . Molecular and Cellular Neurosciences,1994 ,5(2) :145~152
|
| ［20］ |
Holcomb I N, Kabakoff R C, Chan B, et al. FIZZ1, a novel cysteinerich secreted protein associated with pulmonary inflammation,defines a new gene family. EMBO J ,2000，19(15):4046~4055
|
| ［21］ |
Yun R J,Xie S S,Chen J S, et al. The effects of PACAP and related peptides on leptin, soluble leptin receptor and resistin in normal condition and LPSinduced inflammation. Peptides ,2009,30(8):1456~1459
|
| ［22］ |
Lehrke M, Reilly M P, Millington S C, et al.An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med ,2004,1(2):e45
|
| ［23］ |
Delgado M,Pozo D,Martinez C, et al.Vasoactive Intestinal Peptide and Pituitary Adenylate CyclaseActivating Polypeptide Inhibit EndotoxinInduced TNFα Production by Macrophages: In Vitro and In Vivo Studies. Immunology, 1999, 162(4): 2358~2367
|
| ［24］ |
Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem ,1976,72 (12): 248~254
|
| ［25］ |
Delgado M,Ganea D. Cutting edge: is vasoactive intestinal peptide a type 2 cytok ine .J Immunol,2001, 166 (5) : 2907~2912
|
| ［26］ |
Delgado M,Abad C, Martinez C, et al.Vasoactive intestinal peptide prevents experimental arthritis by downregulating both auto immune and inflammatory components of the disease.J Nat Med, 2001, 7 (5) : 563~568
|
| ［27］ |
Tuncel N,Tore F, Sahinturk V,et al. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock.Peptides, 2000, 21 (1) : 81~89
|
| ［28］ |
Keino H, Kezuka T, Takeuchi M,et al. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol, 2004, 122 (8) : 1779~1784
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
